SCHEMBL10220599

SCHEMBL10220599

CNc1nc2c(s1)C(=O)c1ccccc1C2=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 5/20 0.51
TDO2 P48775 3/20 0.51
ALDH1A1 P00352 5/20 0.43
MAPT P10636 4/20 0.43
KDM4E B2RXH2 2/20 0.43
BCL2 P10415 1/20 0.41
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
AHR P35869 1/20 0.41
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
EGFR P00533 1/20 0.38
PABPC1 P11940 1/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
JUN P05412 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1287081 0.81 BCL2 (0.49) IDO1TDO2ALDH1A1MAPTBCL2
SCHEMBL7816362 0.77 IDO1 (0.55) IDO1TDO2ALDH1A1MAPTRAB9A
SCHEMBL1287135 0.77 IDO1 (0.59) IDO1TDO2ALDH1A1MAPTKDM4E
SCHEMBL1287142 0.76 RAB9A (0.50) IDO1TDO2ALDH1A1MAPTKDM4E
SCHEMBL1287130 0.76 BCL2 (0.48) IDO1TDO2ALDH1A1MAPTKDM4E
SCHEMBL1287124 0.76 MEN1 (0.51) IDO1TDO2ALDH1A1MAPTKDM4E
SCHEMBL7818266 0.74 IDO1 (0.55) IDO1TDO2ALDH1A1MAPTKDM4E
SCHEMBL1287137 0.74 IDO1 (0.55) IDO1TDO2ALDH1A1MAPTKDM4E
SCHEMBL10719313 0.73 IDO1 (0.51) IDO1TDO2ALDH1A1MAPTRAB9A
SCHEMBL1287085 0.73 DHODH (0.47) IDO1TDO2MAPTBCL2CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9040713-B2 Methods of managing blood sugar levels and compositions related thereto EMORY UNIVERSITY (US) 2015-05-26 US disclosed
US-9040713-B2 Methods of managing blood sugar levels and compositions related thereto EMORY UNIVERSITY (US) 2015-05-26 US disclosed
US-9040713-B2 Methods of managing blood sugar levels and compositions related thereto EMORY UNIVERSITY (US) 2015-05-26 US disclosed
US-20130158082-A1 METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO EMORY UNIVERSITY (US) 2013-06-20 US disclosed
US-20130158082-A1 METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO EMORY UNIVERSITY (US) 2013-06-20 US disclosed
US-20130158082-A1 METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO EMORY UNIVERSITY (US) 2013-06-20 US disclosed
WO-2012047628-A2 METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO EMORY UNIVERSITY (US) 2012-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158082-A1 METHODS OF MANAGING BLOOD SUGAR LEVELS AND COMPOSITIONS RELATED THERETO SLC5A1, SLC2A1, SLC5A2 IDO1 3203/4885TDO2 2213/4885ALDH1A1 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.